ストックスクリーナーアプリを入手
62.38
1.35%
0.83
アフターアワーズ：
60.87
-1.51
-2.42%
前日終値:
$61.55
開ける：
$61.73
24時間の取引高:
2.32M
Relative Volume:
0.77
時価総額：
$8.74B
収益：
$181.74M
当期純損益:
$-143.97M
株価収益率:
-44.88
EPS:
-1.39
ネットキャッシュフロー:
$9.60M
1週間 パフォーマンス:
-3.50%
1か月 パフォーマンス:
-5.38%
6か月 パフォーマンス:
+250.45%
1年 パフォーマンス:
+235.92%
1日の値動き範囲:
$61.17
$63.13
1週間の範囲:
$60.34
$68.44
52週間の値動き範囲:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
62.38 | 8.62B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharma stock outlook: Goldman Sachs sees 2026 catalysts ahead - Investing.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) added to S&P 400Biotechnology - marketscreener.com
Top Pharmaceutical Stocks To Follow TodayFebruary 8th - MarketBeat
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026 - TipRanks
Best Pharmaceutical Stocks To Add to Your WatchlistFebruary 7th - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Principal Financial Group Inc. Buys 157,035 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality - Sahm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript - Insider Monkey
Arrowhead gains approval of Redemplo in China for high triglycerides - MSN
More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships - Sahm
Arrowhead Pharmaceuticals (ARWR) Reports Strong Q1 2026 Performa - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - BioSpace
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q1 2026 Earnings Conference - 富途牛牛
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highl - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arrowhead Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com India
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M - marketscreener.com
Arrowhead (ARWR) Set to Join S&P 400 Index - GuruFocus
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - Yahoo Finance
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains? - Sahm
Trading Action: Is Arrowhead Pharmaceuticals Inc gaining market share2025 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia - Sahm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation - Sahm
The Technical Signals Behind (ARWR) That Institutions Follow - Stock Traders Daily
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals, Inc. $ARWR is Privium Fund Management B.V.'s 9th Largest Position - MarketBeat
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Can Arrowhead Pharmaceuticals Inc. weather a recessionJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Mfd.ru
Is Arrowhead Pharmaceuticals Inc. stock a buy or sellLayoff News & Precise Swing Trade Entry Alerts - mfd.ru
How cyclical is Arrowhead Pharmaceuticals Inc.’s revenue stream2025 Valuation Update & Scalable Portfolio Growth Ideas - Mfd.ru
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):